Pfizer: Xeljanz Study in Juvenile Idiopathic Arthritis Met Primary Endpoint
12 Noviembre 2019 - 6:29AM
Noticias Dow Jones
By Colin Kellaher
Pfizer Inc. (PFE) Tuesday said a phase 3 investigational study
of Xeljanz in children and adolescents with juvenile idiopathic
arthritis met its primary endpoint.
The New York drug maker said the occurrence of disease flare in
patients with polyarticular juvenile idiopathic arthritis treated
with Xeljanz was significantly lower than patients treated with
placebo at week 44.
Pfizer said it plans to file for U.S. Food and Drug
Administration approval of Xeljanz in juvenile idiopathic arthritis
in 2020.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 12, 2019 07:14 ET (12:14 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Pfizer (NYSE:PFE)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
